Inhibition of EP300 and DDR1 synergistically alleviates pulmonary fibrosis in vitro and in vivo

ConclusionsThe EP300 siRNA and inhibitors sensitized DDR1 inhibitors in our pulmonary fibrosis models in vitro and in vivo, implicating a combined inhibition of DDR1 with EP300 as potential therapies for IPF.Graphical abstractThe EP300 siRNA and inhibitors sensitized DDR1 inhibitors in pulmonary fibrosis models in vitro and in vivo, implicating a combined inhibition of DDR1 with EP300 as potential therapies for IPF.

Source: Biomedicine and Pharmacotherapy - July 31, 2018 Category: Drugs & Pharmacology Source Type: research